Session Title: Quick Fire Free Paper Session 02
Session Date/Time: Thursday 26/09/2013 | 14:30-16:00
Paper Time: 14:50
Venue: Hall G1 (Level 2)
First Author: V.Dzinic SERBIA
Co Author(s): A. Oros M. Dzinic
to investigate the effects of intravitreal anti-VEFG (bevacizumab) application in patients with branch retinal vein occlusion.
Clinical center Vojvodine, University Eye clinic, Eye center Dzinic
during 18 months period 24 patients (24 eyes) were followed. Mean age was 63 ± 11, 6 male and 18 female. In 20 eyes diagnose was set within 2 weeks after visual disturbances and in four eyes more than one month. Visual acuity (VA) testing (Snellen chart), biomicrosopy, ophthalmoscopy, IOP and SD-OCT were conducted at baseline and follow up visits. FA was conducted at baseline and further as needed. In all patients, branch retinal vein occlusion with cystoids macular edema was found. All patients received intravitreal injection 1,25mg (0,05ml) of bevacizumab, during initial treatment and retreatment. The average number of injection per patient was 1,8 ± 0, 7. All patients used local non-steroid antinflamatory therapy (NSAID) 4-6 weeks after injection. In four eyes we repeated FA and did laser photocoagulation (peripheral and grid). Follow up visits were conducted at the first and 7th day after injection and every 4-6 weeks after. Last follow up visit was 18 months after the diagnose have been set.
Mean VA before treatment was 0.26 ± 0.2 and average macular thickness 534±245µm. After 6 months, average macular thickness was 389±181µm and mean VA 0.58±0.32. At the last follow up average VA was 0.62 ± 0.36 and macular thickness 332±191µm. Improvement was achieved in 20 (83%) eyes, stabilization in two eyes (8.5%) and worsening in two eyes (8.5%).
According to our study intravitreal application of bevacizumab have beneficial effects in patients with branch retinal vein occlusion. Application of therapy as soon as possible and better visual acuity at the time of diagnoses has beneficial effects on the therapy outcome. Anti-VEGF seems to be promising treatment option for improvement and stabilization in VA and macular thickness (p<0.01) during follow up period. Long-term follow-up is required to evaluate the safety and treatment durability using bevacizumab. Financial disclosure: NO